Johnson and Johnson Newswire

Johnson and Johnson Newswire

Comprehensive Real-Time News Feed for Johnson and Johnson.

Results 1 - 20 of 4,870 in Johnson and Johnson

  1. Johnson & Johnson (JNJ) Price Target Raised to $133.00Read the original story w/Photo

    51 min ago | Daily Political

    Royal Bank Of Canada currently has an outperform rating on the stock. Shares of Johnson & Johnson traded down 0.45% during mid-day trading on Wednesday, reaching $124.47.

    Comment?

  2. Johnson & Johnson's (JNJ) "Outperform" Rating...Read the original story w/Photo

    51 min ago | Daily Political

    BMO Capital Markets currently has a $132.00 price target on the stock. Shares of Johnson & Johnson traded down 0.45% during trading on Wednesday, hitting $124.47.

    Comment?

  3. Smith & Nephew Continues To ImpressRead the original story w/Photo

    1 hr ago | Seeking Alpha

    The medtech space has attracted me for some time and, recently, I added some of SNN's NYSE-listed ADRs. The medical tech space has always interested me.

    Comment?

  4. Johnson & Johnson: Great Quality, But Stock Has No Margin Of SafetyRead the original story w/Photo

    1 hr ago | Seeking Alpha

    This piece is in response to Bob Ciura's article where he states that Johnson & Johnson is a quality stock and that it is "cheap". Based on the results of my analysis, I cannot agree with Bob Ciura and I find that Johnson & Johnson is overvalued.

    Comment?

  5. J&J Earnings Beat Analysts' Estimates as Drug Sales IncreaseRead the original story

    1 hr ago | The Washington Post

    Johnson & Johnson posted second-quarter earnings that beat analysts' estimates, aided by the growing pharmaceutical division that is home to blockbuster products such as arthritis treatment Remicade. Shares of the world's biggest maker of health-care products have been trading at all-time highs as J&J relies on prescription medicines like Remicade and psoriasis drug Stelara to drive sales and stem a slowdown from the medical devices division.

    Comment?

  6. ReVision Optics Appoints Frank Shields Vice President of Sales WorldwideRead the original story w/Photo

    6 hrs ago | Freshnews

    ReVision Optics, Inc. , a leader in implantable presbyopia-correcting corneal inlay technology, announces the appointment of Frank Shields to the newly created position of Vice President of Sales Worldwide effective immediately. Mr. Shields brings more than 25 years of experience in surgical sales at leading ophthalmic companies and has been instrumental in the launch of several leading ophthalmic lens products.

    Comment?

  7. Our children, our future - bridging the partisan divideRead the original story w/Photo

    8 hrs ago | The Hill

    This week, as they did last week in Cleveland, hundreds of interest groups and lobbyists will be in Philadelphia for the presidential convention. However, one critical group is not present - our children.

    Comment?

  8. 30+ at Johnson & Johnson's DePuy Subsidiary Will Stand Trial on Fraud-Related ChargesRead the original story

    19 hrs ago | BioSpace

    A total of 30 people are to stand trial on fraud-related charges in connection to the sale of orthopedic equipment to Greek hospitals by a subsidiary of Johnson & Johnson between 2000 and 2006, according to court documents seen by Kathimerini. Executives of the company concerned, DePuy, are alleged to have bribed Greek doctors in order to secure the contracts for the equipment.

    Comment?

  9. Why I'm Easing Off Johnson & JohnsonRead the original story w/Photo

    12 hrs ago | Seeking Alpha

    Medical conglomerate Johnson & Johnson has been on a roll for the last couple years. The company has three businesses: Medical devices, consumer products and pharmaceuticals.

    Comment?

  10. Monday interview: David McMillan, MD of LifeScan ScotlandRead the original story

    19 hrs ago | Scotsman.com

    Celebrating his 50th birthday this year, David McMillan of medical device firm LifeScan Scotland, part of the Johnson & Johnson group, has set himself 50 new tasks to complete in as many weeks. The list includes everything from going to the opera to watching the Godfather trilogy, and even learning to kitesurf, which may require some international travel to find a suitable school.

    Comment?

  11. Johnson & Johnson (JNJ) Shares Bought by RMB Capital Management LLCRead the original story w/Photo

    23 hrs ago | Daily Political

    RMB Capital Management LLC raised its stake in Johnson & Johnson by 20.9% during the first quarter, Holdings Channel reports. The institutional investor owned 5,881 shares of the company's stock after buying an additional 1,015 shares during the period.

    Comment?

  12. Johnson & Johnson (JNJ) Stake Increased by Prudential Financial Inc.Read the original story w/Photo

    23 hrs ago | Daily Political

    Prudential Financial Inc. raised its position in shares of Johnson & Johnson by 4.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 6,164,877 shares of the company's stock after buying an additional 244,850 shares during the period.

    Comment?

  13. DNC events for Monday, July 25Read the original story w/Photo

    Friday Jul 22 | Philly.com

    Though parties and fund-raisers were scheduled over the weekend, Monday marks the official start of the Democratic National Convention in Philadelphia. Officially sanctioned, star-studded events will be scattered through Center City before the gavel sounds in the late afternoon for the main event at the Wells Fargo Center.

    Comment?

  14. 3 Important Takeaways From Johnson & Johnson's Second-Quarter EarningsRead the original story w/Photo

    Yesterday | The Motley Fool

    ... l's clients may have positions in the companies mentioned. The Motley Fool owns shares of and recommends Johnson and Johnson. Try any of our Foolish newsletter services . We Fools may not all hold the same opinions,

    Comment?

  15. The Growing Presence of Legacy Companies at Cannes: MediaLink's HomonoffRead the original story

    Yesterday | Beet.TV

    Cannes Lions wasn't always a stop on the annual tour for legacy media companies. But that's been changing.

    Comment?

  16. Traders Buy Shares of Johnson & Johnson (JNJ) on WeaknessRead the original story w/Photo

    Yesterday | Daily Political

    Traders purchased shares of Johnson & Johnson on weakness during trading hours on Friday. $222.43 million flowed into the stock on the tick-up and $114.14 million flowed out of the stock on the tick-down, for a money net flow of $108.29 million into the stock.

    Comment?

  17. What To Do When A Stock Overshoots Fair Value: Parker Hannifin And Johnson And Johnson As CasesRead the original story w/Photo

    Yesterday | Seeking Alpha

    ... is dragged upward by two holdings which have gone up quite a bit from my average purchase price -- Johnson and Johnson (NYSE: JNJ ) and Parker Hannifin (NYSE: PH ). I consider both JNJ and PH to be overpriced and would not buy more at the present ...

    Comment?

  18. Concorde Asset Management LLC Has $658,000 Position in Johnson & JohnsonRead the original story w/Photo

    Yesterday | Daily Political

    Concorde Asset Management LLC boosted its stake in shares of Johnson & Johnson by 42.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission . The firm owned 5,432 shares of the company's stock after buying an additional 1,621 shares during the period.

    Comment?

  19. Capital Investment Advisors LLC Purchases 7,853 Shares of Johnson & JohnsonRead the original story w/Photo

    Yesterday | Daily Political

    Capital Investment Advisors LLC boosted its stake in shares of Johnson & Johnson by 7.6% during the second quarter, Holdings Channel reports. The fund owned 110,817 shares of the company's stock after buying an additional 7,853 shares during the period.

    Comment?

  20. Johnson & Johnson: A Dividend King With 54 Years Of Dividend IncreasesRead the original story w/Photo

    Yesterday | Seeking Alpha

    Johnson & Johnson is extremely diversified in the medical health field with new drugs leading the way. The company is a defensive business that will make money in a recession.

    Comment?